Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Norditropin in children with Noonan syndrome: effects on linear growth and final height
2005-000042-37Phase 3Completed
- Sponsor
- Novo Nordisk
- Start
- Apr 2005
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, single-arm trial of somatropin in Noonan syndrome, sponsored by Novo Nordisk. Primary endpoint: Final height. Started Apr 2005; status: completed.
02
Drugs
somatropin
03
Conditions
Noonan syndrome
Beyond the preview
Go deeper on 2005-000042-37.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-000042-37.